There was a non-significant trend towards a higher mean body fat percentage loss in diabetic patients experiencing T2D improvement (defined as HbA1c below 6.5% at 12-month follow-up without insulin, GLP-1 analogs or oral anti-diabetic medication) during 12 months of weight loss (p = 0.085; Figure 5D), whereas NFS changes were not different for unimproved and improved T2D individuals (Figure 5E). The gene discussed is INS; the disease is type 2 diabetes mellitus.